ctDNA-Guided Atezolizumab in Muscle-Invasive Bladder Cancer: FDA Approves Adjuvant Therapy in MRD-Positive Patients After Cystectomy

KEY FINDINGS

• FDA approval: In May 2026 the FDA approved adjuvant atezolizumab (Tecentriq) in patients with muscle-invasive bladder cancer (MIBC) found to have ctDNA-detected minimal residual disease (MRD) after radical cystectomy.
• DFS gain: In the randomized controlled IMvigor011 trial (n=250), atezolizumab increased disease-free survival from 4.8 months to 9.9 months (HR 0.64; p=0.0047).
• OS gain: Overall survival was extended from 21.1 months to 32.8 months (HR 0.59).
• Companion diagnostic: Signatera CDx was designated as the approved companion diagnostic for ctDNA MRD detection.
• Guideline update: The NCCN added ctDNA-MRD testing to its guideline as a prognostic and predictive biomarker in bladder cancer for the first time (Category 1).

Background and Clinical Need

Muscle-invasive bladder cancer (MIBC; ≥T2) is a disease at high risk of recurrence after cystectomy. Although long-term survival improves markedly in the patient subgroup responding to neoadjuvant chemotherapy, recurrence rates remain in the region of 40-60% in patients without a pathological response or with pN+ disease.

Until now, adjuvant immunotherapy strategies have relied on histopathological criteria for patient selection; however, this approach led both to overtreatment and undertreatment. Detection of minimal residual disease (MRD) based on circulating tumour DNA (ctDNA) offers a powerful biomarker platform for monitoring micrometastatic disease in real time.

Why it matters: ctDNA-MRD showed that patients who remained negative for 12 months after cystectomy had a 24-month disease-free survival rate of 88%; this finding supports a "watch and wait" approach while justifying the initiation of immunotherapy in positive patients.

Study Design: IMvigor011

Phase 3 · Randomized · Double-blind · Placebo-controlled · Trial code: NCT04660344

This is a multicentre, randomized, double-blind, placebo-controlled trial. It enrolled MIBC patients who had undergone radical cystectomy plus lymphadenectomy and were found to be MRD-positive within 12 months on serial ctDNA MRD assessment beginning at least 6 weeks after cystectomy.

Key Results

Companion diagnostic: Signatera CDx - Natera's personalised, tumour-informed, multiplex PCR-NGS-based liquid biopsy test. The FDA has approved this test as a companion diagnostic for selecting atezolizumab therapy in ctDNA MRD-positive MIBC patients.

Implications for Clinical Practice

1. The era of personalised adjuvant therapy begins

Instead of giving immunotherapy to every patient after cystectomy, real-time MRD monitoring with ctDNA now makes it possible to treat only the patients who need it. This approach reduces both overtreatment and unnecessary side effects.

2. Post-cystectomy surveillance protocols need updating

With the NCCN's Category 1 recommendation, serial Signatera CDx tests should be performed for 12 months after cystectomy in patients with no prior ICI use. Starting atezolizumab in every patient who becomes positive is now a standard treatment option.

3. ctDNA-negative patients are protected from unnecessary treatment

A 24-month DFS rate of 88% has been demonstrated in patients who remain ctDNA-negative for 12 months. Active surveillance can continue in these patients without starting adjuvant immunotherapy.

4. Clinical validation through debate at the EAU 2026 congress

At EAU 2026, in the debate titled "Should ctDNA guide adjuvant decisions?", views in favour of this approach were defended with strong evidence. European and American guidelines are being shaped together in this direction.

5. Test access and cost

Signatera CDx is not yet routinely reimbursed in many countries, including Türkiye. Securing access to the test remains a critical obstacle to clinical implementation.

Conclusion

The FDA approval of atezolizumab and the NCCN's Category 1 recommendation for ctDNA-MRD are concrete indications of a paradigm shift in the management of muscle-invasive bladder cancer. Liquid biopsy-based biomarkers now play a decisive role not only in research but in day-to-day oncology practice.

This approval will allow the post-cystectomy period in bladder cancer - often described as a "silent killer" - to be managed in a smarter, more personalised way. In the coming years, work on expanding ctDNA panels and easing access to the test in Türkiye should move to the centre of the agenda.

References

• FDA. FDA approves atezolizumab for adjuvant treatment of muscle invasive bladder cancer in patients with molecular residual disease. May 2026. - fda.gov
• Genentech Press Release. FDA Approves Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment. 15 May 2026. - gene.com
• Urology Times. FDA approves atezolizumab as adjuvant therapy for MIBC guided by ctDNA. 2026. - urologytimes.com
• Urology Times. NCCN recommends ctDNA-MRD testing to guide adjuvant treatment post-cystectomy. 2026. - urologytimes.com
• UroToday. NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update. 2026. - urotoday.com
• ASCO Post. IMvigor011 Subgroup Analysis: Role of ctDNA in Guiding Adjuvant Treatment for MIBC. March 2026. - ascopost.com
• CancerNetwork. FDA Approves Atezolizumab in MIBC Post-Cystectomy with ctDNA MRD. 2026. - cancernetwork.com
• UroToday. EAU 2026: ctDNA Should Guide Adjuvant Decisions - Debate Summary. 2026. - urotoday.com